NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/04/2023
Voltar para busca
Dado oficial do USPTO
AXIAL THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
AXIAL THERAPEUTICS
ST13
US500000088641428Classe
1, 5, 42, 44
Pedido
88641428
Registro
7037386
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
25/04/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
03/10/2019
Data de registro
25/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/04/2023
Última transação
25/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/10/2022
Primeiro uso no comércio
01/10/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
WOBURN, MA, US
Examinador
FITZSIMONS,MICHAEL R
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
AXIAL THERAPEUTICS, INC.
Axial Biotherapeutics, Inc.
Representantes
Ian W. Gillies KNOBBE, MARTENS, OLSON & BEAR, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalsbiochemicalscellsmicrobes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparationsfor in vitro and in vivo scientific or research usefor use in industry and science; chemicalbiochemical and microbial productsone or more of small moleculesproteinsantibodiesnucleic acidsprobiotic bacteriaprobiotic bacterial culturesmicrobes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatmentpreventiondetection of central nervous system diseases and disorderscancertumorsfibrosisinflammationmicrobe-related and microbiome-related conditionsgastrointestinal and immunological diseasesany disease or disorder associated with intestinal permeabilityleaky gutamyloids
Classe 5
Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatmentpreventiondetection of central nervous system diseases and disorderscancertumorsfibrosisinflammationmicrobe-related and microbiome-related conditionsgastrointestinal and immunological diseasesany disease or disorder associated with intestinal permeabilityleaky gutamyloids; chemicalbiochemical and microbial productsone or more of small moleculesproteinsantibodiesnucleic acidsprobiotic bacteriaprobiotic bacterial culturesmicrobes being pharmaceutical preparations and substances for the treatmentpreventiondetection of central nervous system diseases and disorderscancertumorsfibrosisinflammationmicrobe-related and microbiome-related conditionsgastrointestinal and immunological diseasesany disease or disorder associated with intestinal permeabilityleaky gutamyloids
Classe 42
Providing medical and scientific research information in the fields of pharmaceuticalsbiochemistrybiotechnologyclinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistrybiotechnologyconducting clinical trials for others
Classe 44
Providing medical information in the fields of diagnosticprophylactictherapeutic properties of probiotic or microbe-targeted pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
25/04/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
21/03/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
18/03/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/02/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
21/02/2023
EX2G
SOU EXTENSION 2 GRANTED
21/02/2023
IUAF
USE AMENDMENT FILED
17/02/2023
EXT2
SOU EXTENSION 2 FILED
17/02/2023
EEXT
SOU TEAS EXTENSION RECEIVED
17/02/2023
EISU
TEAS STATEMENT OF USE RECEIVED
17/02/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/10/2022
EX1G
SOU EXTENSION 1 GRANTED
04/10/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/09/2022
EXT1
SOU EXTENSION 1 FILED
22/08/2022
EEXT
SOU TEAS EXTENSION RECEIVED
22/08/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/02/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/12/2021
PUBO
PUBLISHED FOR OPPOSITION
28/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/12/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
22/11/2021
ALIE
ASSIGNED TO LIE
18/11/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/11/2021
DOCK
ASSIGNED TO EXAMINER
15/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/10/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/10/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/10/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/06/2021
GNRT
NON-FINAL ACTION E-MAILED
04/06/2021
CNRT
NON-FINAL ACTION WRITTEN
04/06/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
19/04/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
28/03/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
24/03/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/02/2021
EEXT
SOU TEAS EXTENSION RECEIVED
08/02/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
27/10/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/09/2020
PUBO
PUBLISHED FOR OPPOSITION
01/09/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/07/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/01/2020
GNRT
NON-FINAL ACTION E-MAILED
09/01/2020
CNRT
NON-FINAL ACTION WRITTEN
09/01/2020
DOCK
ASSIGNED TO EXAMINER
08/01/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/10/2019
NWAP
NEW APPLICATION ENTERED
07/10/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AXIAL THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.